GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exact Therapeutics AS (OSL:EXTX) » Definitions » EBITDA Margin %

Exact Therapeutics AS (OSL:EXTX) EBITDA Margin % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Exact Therapeutics AS EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Exact Therapeutics AS's EBITDA for the six months ended in Dec. 2023 was kr-25.45 Mil. Exact Therapeutics AS's Revenue for the six months ended in Dec. 2023 was kr0.00 Mil. Therefore, Exact Therapeutics AS's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.


Exact Therapeutics AS EBITDA Margin % Historical Data

The historical data trend for Exact Therapeutics AS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Therapeutics AS EBITDA Margin % Chart

Exact Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial - - - - -

Exact Therapeutics AS Semi-Annual Data
Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Exact Therapeutics AS's EBITDA Margin %

For the Biotechnology subindustry, Exact Therapeutics AS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Therapeutics AS's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exact Therapeutics AS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Exact Therapeutics AS's EBITDA Margin % falls into.



Exact Therapeutics AS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Exact Therapeutics AS's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-46.205/0
= %

Exact Therapeutics AS's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-25.446/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exact Therapeutics AS  (OSL:EXTX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Exact Therapeutics AS EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Exact Therapeutics AS's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Therapeutics AS (OSL:EXTX) Business Description

Traded in Other Exchanges
N/A
Address
Ostre Aker vei 19, Oslo, NOR, 0581
Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing a technology platform for therapeutic enhancement - Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.

Exact Therapeutics AS (OSL:EXTX) Headlines

No Headlines